Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children

PLoS ONE

Volumn 4, Issue 10, 2009, Pages

  Sirima, Sodiomon B ^a,b   Tiono, Alfred B ^a   Ouédraogo, Alphonse ^a   Diarra, Amidou ^a   Ouédraogo, André Lin ^a   Yaro, Jean Baptiste ^a   Ouédraogo, Espérance ^a   Gansané, Adama ^a   Bougouma, Edith C ^a   Konaté, Amadou T ^a   Kaboré, Youssouf ^a   Traoré, Abdoulaye ^a,b   Roma, Chilengi ^c   Soulama, Issiaka ^a   Luty, Adrian J F ^d   Cousens, Simon ^e   Nébié, Issa ^a  

^a Burkina Faso   (Burkina Faso)

^b Groupe d'Action et de Recherche en Santé   (Burkina Faso)

^c African Malaria Network Trust   (Tanzania)

^d RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN G4; IMMUNOGLOBULIN M; MALARIA VACCINE; MEROZOITE SURFACE PROTEIN 3 ANTIBODY; MEROZOITE SURFACE PROTEIN 3 LONG SYNTHETIC PEPTIDE VACCINE; PROTEIN ANTIBODY; RECOMBINANT HEPATITIS B VACCINE; UNCLASSIFIED DRUG; MEROZOITE SURFACE PROTEIN 3, PLASMODIUM; PARASITE ANTIGEN; PEPTIDE; PROTOZOAL PROTEIN;

AFRICA; AGE DISTRIBUTION; ANOREXIA; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CHILD SAFETY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG ANTIGENICITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG FEVER; DRUG SAFETY; HEPATITIS A; HUMAN; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INJECTION SITE SWELLING; IRRITABILITY; MALARIA; OUTCOME ASSESSMENT; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PLASMODIUM FALCIPARUM; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SKIN DISEASE; SYMPTOMATOLOGY; UNSPECIFIED SIDE EFFECT; WOUND; BURKINA FASO; CHEMISTRY; GENETICS; IMMUNOLOGY; INFANT; MEROZOITE; METABOLISM; METHODOLOGY; TIME; TREATMENT OUTCOME;

PLASMODIUM FALCIPARUM;

ANTIGENS, PROTOZOAN; BURKINA FASO; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HUMANS; INFANT; MALARIA; MALARIA VACCINES; MEROZOITES; PEPTIDES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS; RESEARCH DESIGN; TIME FACTORS; TREATMENT OUTCOME;

EID: 70449552811     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0007549     Document Type: Article

References (22)

1. Guerin PJ, Olliaro P, Nosten F, Druilhe P, Laxminarayan R, et al. (2002) Malaria: current status of control, diagnosis, treatment, and a proposed agenda for research and development. Lancet Infect Dis 2(9): 564-573.
2. Soe S, Theisen M, Roussilhon C, Aye KS, Druilhe P (2004) Association between protection against clinical malaria and antibodies to merozoite surface antigens in an area of hyperendemicity in Myanmar: complementarity between responses to merozoite surface protein 3 and the 220-kilodalton glutamate-rich protein. Infect Immun 72(1): 247-252.
3. Oeuvray C, Theisen M, Rogier C, Trape JF, Jepsen S, et al. (2000) Cytophilic immunoglobulin responses to Plasmodium falciparum glutamate-rich protein are correlated with protection against clinical malaria in Dielmo, Senegal. Infect Immun 68(5): 2617-2620.
4. Oeuvray C, Bouharoun-Tayoun H, Gras-Masse H, Bottius E, Kaidoh T, et al. (1994) Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes. Blood 84(5): 1594-1602.
5. Tebo AE, Kremsner PG, Luty AJ (2001) Plasmodium falciparum: a major role for IgG3 in antibody-dependent monocyte-mediated cellular inhibition of parasite growth in vitro. Exp Parasitol 98(1): 20-28.
6. Dodoo D, Theisen M, Kurtzhals JA, Akanmori BD, Koram KA, et al. (2000) Naturally acquired antibodies to the glutamate-rich protein are associated with protection against Plasmodium falciparum malaria. J Infect Dis 181(3): 1202-1205.
7. Druilhe P, Bouharoun-Tayoun H (2002) Antibody-dependent cellular inhibition assay. Methods Mol Med 72: 529-534.
8. Ndungu FM, Bull PC, Ross A, Lowe BS, Kabiru E, et al. (2002) Naturally acquired immunoglobulin (Ig)G subclass antibodies to crude asexual Plasmodium falciparum lysates: evidence for association with protection for IgG1 and disease for IgG2. Parasite Immunol 24(2): 77-82.
9. Jordan SJ, Branch OH, Castro JC, Oster RA, Rayner JC (2009) Genetic diversity of the malaria vaccine candidate Plasmodium falciparum merozoite surface protein-3 in a hypoendemic transmission environment. Am J Trop Med Hyg 80(3): 479-486.
10. Audran R, Cachat M, Lurati F, Soe S, Leroy O, et al. (2005) Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infect Immun 73(12): 8017-8026.
11. Druilhe P, Spertini F, Soesoe D, Corradin G, Mejia P, et al. (2005) A malaria vaccine that elicits in humans antibodies able to kill Plasmodium falciparum. PLoS Med 2(11): e344.
12. Sirima SB, Nebie I, Ouedraogo A, Tiono AB, Konate AT, et al. (2007) Safety and immunogenicity of the Plasmodium falciparum merozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine 25(14): 2723-2732.
13. Nebie I, Diarra A, Ouedraogo A, Soulama I, Bougouma EC, et al. (2008) Humoral responses to Plasmodium falciparum blood-stage antigens and association with incidence of clinical malaria in children living in an area of seasonal malaria transmission in Burkina Faso, West Africa. Infect Immun 76(2): 759-766.
14. McColl DJ, Anders RF (1997) Conservation of structural motifs and antigenic diversity in the Plasmodium falciparum merozoite surface protein-3 (MSP-3). Mol Biochem Parasitol 90(1): 21-31.
15. Bouharoun-Tayoun H, Druilhe P (1992) Plasmodium falciparum malaria: evidence for an isotype imbalance which may be responsible for delayed acquisition of protective immunity. Infect Immun 60(4): 1473-1481.
16. Bouharoun-Tayoun H, Druilhe P (1992) Antibodies in falciparum malaria: what matters most, quantity or quality? Mem Inst Oswaldo Cruz 87 Suppl 3: 229-234.
17. Sabchareon A, Burnouf T, Ouattara D, Attanath P, Bouharoun-Tayoun H, et al. (1991) Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 45(3): 297-308.
18. Jafarshad A, Dziegiel MH, Lundquist R, Nielsen LK, Singh S, et al. (2007) A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimulation of monocytes FcgammaRII and FcgammaRIII. J Immunol 178(5): 3099-3106.
19. Bouharoun-Tayoun H, Attanath P, Sabchareon A, Chongsuphajaisiddhi T, Druilhe P (1990) Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. J Exp Med 172(6): 1633-1641.
20. Bouharoun-Tayoun H, Oeuvray C, Lunel F, Druilhe P (1995) Mechanisms underlying the monocyte-mediated antibody-dependent killing of Plasmodium falciparum asexual blood stages. J Exp Med 182(2): 409-418.
21. Druilhe P, Perignon JL (1994) Mechanisms of defense against P. falciparum asexual blood stages in humans. Immunol Lett 41(2-3): 115-120.
22. Oeuvray C, Bouharoun-Tayoun H, Grass-Masse H, Lepers JP, Ralamboranto L, et al. (1994) A novel merozoite surface antigen of Plasmodium falciparum (MSP-3) identified by cellular-antibody cooperative mechanism antigenicity and biological activity of antibodies. Mem Inst Oswaldo Cruz 89 Suppl 2: 77-80.